8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Crimean-Congo Haemorrhagic Fever Vaccine (CCHFVaccine)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2022,
Natural epidemics and outbreaks of emerging viral epidemics are growing problems internationally. The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) disease on a global basis. The proposed work program on CCHF virus aims to build a multidisciplinary researc ...
Voir le projet
15
Participants partenaires
TERMINÉ
Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)
Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,
Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Voir le projet
26
Participants partenaires
TERMINÉ
Chimeric Antigen Receptors (CARs) for Advanced Therapies (CARAT)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T-cells specifically towards killing of cancer cells. Recent success stories of cancer therapy with CAR modified T-c ...
Voir le projet
9
Participants partenaires
TERMINÉ
TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Voir le projet
49
Participants partenaires
TERMINÉ
Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)
Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,
The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet
39
Participants partenaires
TERMINÉ
Integrated Approaches to Food Allergen and Allergy Risk Management (IFAAM)
Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,
Up to 20 million European citizens suffer from food allergy. However management of both food allergy (by patients and health practitioners) and allergens (by industry) is thwarted by lack of evidence to either prevent food allergy developing or protect adequately those who are already allergic. iFAAM will develop evidence-based approaches and tools for MANAGEMENT of ALLERGENS in FOOD and integrate ...
Voir le projet
46
Participants partenaires
TERMINÉ
Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD) (TARGETAMD)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
Age-related Macular Degeneration (AMD), a neurodegenerative disease of the retina, is a major cause of blindness in elderly people. Due to the aging population, AMD has been referred to as a “time bomb” in society. In the exudative form of AMD, high levels of vascular endothelial cell growth factor (VEGF) and low levels of pigment-epithelial derived factor (PEDF), an inhibitor of vascularization a ...
Voir le projet
16
Participants partenaires
TERMINÉ
Persisting Transgenesis (PERSIST)
Date du début: 1 janv. 2009, Date de fin: 30 juin 2013,
"For many disabling or fatal diseases, there is pre-clinical or clinical evidence of the potential therapeutic efficacy of gene therapy and, yet, the limitations of current gene transfer technologies have prevented success or even caused serious adverse events leading to termination of trials. PERSIST will explore the use of highly innovative gene-modifying and delivery technologies and capitalize ...
Voir le projet